small molecule

VASCEPA

ICOSAPENT ETHYL

Loss of exclusivityJune 2033latest FDA-listed patent expiry
CompanyAMARIN PHARMACEUTICALS IRELAND LTD

Drug detail

Brand nameVASCEPA
Active ingredientICOSAPENT ETHYL
Strength500MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2017
Marketing statusRX

Listed patents

PatentExpiresType
10792270June 2033use U-2962
10278935June 2033use U-2701
9623001June 2033use U-2698
9693985June 2033use U-2696
9693986June 2033use U-2698
9918954June 2033use U-2699
10278936June 2033use U-2702
10278937June 2033use U-2703
10383840June 2033use U-2704
10555924June 2033use U-2743
10555925June 2033use U-2744
10668042June 2033use U-2841
11000499June 2033use U-3126
10568861June 2033use U-2756
11369582June 2033use U-2841
11298333June 2033use U-3358
10576054June 2033use U-2762
10894028June 2033use U-3053
11116742June 2033use U-3221
10786478June 2033use U-2960
9603826June 2033use U-2696
9610272June 2033use U-2697
9693984June 2033use U-2697
8410086June 2030use U-2688
8669245June 2030use U-2694
8710041June 2030use U-2690
10842768June 2030use U-2688
8501225April 2030use U-1287
8617594April 2030use U-1287
8445003April 2030use U-1287
8623406April 2030use U-2692
8617593April 2030use U-2691
8454994April 2030use U-2689
8642077April 2030use U-2693
8703185April 2030use U-2691
8709475April 2030use U-2689
8691871April 2030use U-2689
10010517April 2030use U-2690
10265287April 2030use U-2700
8445013April 2030use U-1287
8563608April 2030use U-1287
11154526April 2030use U-3240
11717504April 2030use U-3669
10792267April 2030use U-2961
10842766April 2030use U-2997
10881632April 2030use U-3052
11103477April 2030use U-3209
11213504April 2030use U-3292
8298554April 2030product
8546372February 2030use U-1287
8518929February 2030use U-1287
12171738February 2030use U-4105
8426399February 2030use U-1287
8524698February 2030use U-1287
8415335February 2030use U-1287
8680144February 2030use U-2695
8399446February 2030use U-1287
9198892September 2027use U-2706
9700537May 2027use U-2707

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VASCEPA patent cliff — loss of exclusivity June 2033 | CliffBio